Inflammasome activation in chronic glomerular diseases

Current Drug Targets

Volumn 17, Issue 16, 2016, Pages

  Conley, Sabena M ^a   Abais, Justine M ^a   Boini, Krishna M ^b   Li, Pin Lan ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Diabetes mellitus; Glomerulosclerosis; Homocysteine; Inflammasome; Inflammation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADJUVANT; ALUMINUM SALT; AMYLOID BETA PROTEIN; ASBESTOS; CASPASE INHIBITOR; CATHEPSIN B; CHOLESTEROL; HOMOCYSTEINE; HYALURONIC ACID; INFLAMMASOME; INTERLEUKIN 1BETA; ISOLIQUIRITIGENIN; LIPOPOLYSACCHARIDE; MURAMYL DIPEPTIDE; NANOPARTICLE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NIGERICIN; NUCLEIC ACID; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PARTHENOLIDE; REACTIVE OXYGEN METABOLITE; SILICON DIOXIDE; URATE;

ADENOVIRIDAE; CANDIDA ALBICANS; DEGENERATIVE DISEASE; END STAGE RENAL DISEASE; ENDOTHELIUM CELL; ESCHERICHIA COLI; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GLOMERULOPATHY; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INFLUENZA VIRUS; LYSOSOME; METABOLISM; MUCKLE WELLS SYNDROME; NEISSERIA GONORRHOEAE; POTASSIUM TRANSPORT; REVIEW; STAPHYLOCOCCUS AUREUS;

EID: 84997695788     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450117666160401123435     Document Type: Review

References (102)

1. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1betadependent adaptive immunity against tumors. Nat Med 2009; 15(10): 1170-8.
2. Asgari E, Le Friec G, Yamamoto H, et al. C3a modulates IL-1beta secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 2013; 122(20): 3473-81.
3. Kim SM, Lee SH, Kim YG, et al. Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. Am J Physiol Renal Physiol 2015; 308(9): F993-F1003.
4. Kasimsetty SG, DeWolf SE, Shigeoka AA, McKay DB. Regulation of TLR2 and NLRP3 in primary murine renal tubular epithelial cells. Nephron Clin Pract 2014; 127(1-4): 119-23.
5. Wang J, Wen Y, Lv LL, et al. Involvement of endoplasmic reticulum stress in angiotensin II-induced NLRP3 inflammasome activation in human renal proximal tubular cells in vitro. Acta pharmacol Sin 2015; 36(7): 821-30.
6. Zhuang Y, Hu C, Ding G, et al. Albumin impairs renal tubular tight junctions via targeting the NLRP3 inflammasome. Am J Physiol Renal Physiol 2015; 308(9): F1012-19.
7. Abais JM, Zhang C, Xia M, et al. NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia. Antioxid Redox Signal 2013; 18(13): 1537-48.
8. Zhang C, Boini KM, Xia M, et al. Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia. Hypertension 2012; 60(1): 154-62.
9. Segelmark M, Hellmark T. Autoimmune kidney diseases. Autoimmun Rev 2010; 9(5): A366-71.
10. Niemir ZI, Stein H, Dworacki G, et al. Podocytes are the major source of IL-1 alpha and IL-1 beta in human glomerulonephritides. Kidney Int 1997; 52(2): 393-403.
11. Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988; 141(9): 3050-4.
12. Tesch GH, Yang N, Yu H, et al. Intrinsic renal cells are the major source of interleukin-1 beta synthesis in normal and diseased rat kidney. Nephrol Dial Transplant 1997; 12(6): 1109-15.
13. Xia M, Boini KM, Abais JM, Xu M, Zhang Y, Li PL. Endothelial NLRP3 inflammasome activation and enhanced neointima formation in mice by adipokine visfatin. Am J Pathol 2014; 184(5): 1617-28.
14. Abais JM, Xia M, Li G, et al. Nod-like receptor protein 3 (NLRP3) inflammasome activation and podocyte injury via thioredoxin interacting protein (TXNIP) during hyperhomocysteinemia. J Biol Chem 2014; 289(39): 27159-68.
15. Boini KM, Xia M, Abais JM, et al. Activation of inflammasomes in podocyte injury of mice on the high fat diet: Effects of ASC gene deletion and silencing. Biochim Biophys Acta 2014; 1843(5): 836-45.
16. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010; 327(5963): 296-300.
17. Turner CM, Arulkumaran N, Singer M, Unwin RJ, Tam FW. Is the inflammasome a potential therapeutic target in renal disease? BMC Nephrol 2014; 15:21.
18. Faustin B, Lartigue L, Bruey JM, et al. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell 2007; 25(5): 713-24.
19. Boyden ED, Dietrich WF. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 2006; 38(2): 240-4.
20. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011; 477(7366): 592-5.
21. Miao EA, Mao DP, Yudkovsky N, et al. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc Natl Acad Sci USA 2010; 107(7): 3076-80.
22. Zhao Y, Yang J, Shi J, et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 2011; 477(7366): 596-600.
23. Cassel SL, Sutterwala FS. Sterile inflammatory responses mediated by the NLRP3 inflammasome. Eur J Immunol 2010; 40(3): 607-11.
24. Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002; 46(9): 2445-52.
25. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20(3): 319-25.
26. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A: Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 2009; 206(1): 79-87.
27. Thomas PG, Dash P, Aldridge JR, et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 2009; 30(4): 566-75.
28. Muruve DA, Petrilli V, Zaiss AK, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008; 452(7183): 103-7.
29. Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440(7081): 228-32.
30. Duncan JA, Gao X, Huang MT, et al. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J Immunol 2009; 182(10): 6460-9.
31. Joly S, Ma N, Sadler JJ, Soll DR, Cassel SL, Sutterwala FS. Cutting edge: Candida albicans hyphae formation triggers activation of the Nlrp3 inflammasome. J Immunol 2009; 183(6): 3578-81.
32. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440(7081): 237-41.
33. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320(5876): 674-7.
34. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunol 2008; 9(8): 847-56.
35. Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J 2006; 25(21): 5071-82.
36. Li X, Zhang Y, Xia M, Gulbins E, Boini KM, Li PL. Activation of Nlrp3 inflammasomes enhances macrophage lipid-deposition and migration: implication of a novel role of inflammasome in atherogenesis. PLoS One 2014; 9(1): e87552.
37. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013; 493(7434): 674-8.
38. De Nardo D, De Nardo CM, Latz E. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. Am J Pathol 2014; 184(1): 42-54.
39. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nature Immunol 2008; 9(8): 857-65.
40. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464(7293): 1357-61.
41. Yamasaki K, Muto J, Taylor KR, et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 2009; 284(19): 12762-71.
42. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin interacting protein links oxidative stress to inflammasome activation. Nature Immunol 2010; 11(2): 136-40.
43. Xia M, Boini KM, Abais JM, Xu M, Zhang Y, Li PL. Endothelial NLRP3 inflammasome activation and enhanced neointima formation in mice by adipokine visfatin. Am J Pathol 2014; 184(5): 1617-28.
44. Krishnan SM, Sobey CG, Latz E, Mansell A, Drummond GR. IL-1beta and IL-18: inflammatory markers or mediators of hypertension? Br J Pharmacol 2014; 171(24): 5589-602.
45. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13(6): 397-411.
46. Franchi L, Eigenbrod T, Nunez G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 2009; 183(2): 792-6.
47. Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung V. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 2012; 189(8): 4175-81.
48. Haneklaus M, Gerlic M, Kurowska-Stolarska M, et al. H Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol 2012; 189(8): 3795-9.
49. Jin C, Flavell RA. Molecular mechanism of NLRP3 inflammasome activation. J Clin Immunol 2010; 30(5): 628-31.
50. Kahlenberg JM, Dubyak GR. Differing caspase-1 activation states in monocyte versus macrophage models of IL-1beta processing and release. J Leuko Biol 2004; 76(3): 676-84.
51. Gross O, Poeck H, Bscheider M, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 2009; 459(7245): 433-6.
52. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007; 14(9): 1583-9.
53. Dostert C, Guarda G, Romero JF, et al. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One 2009; 4(8): e6510.
54. Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nature Rev Immunol 2010; 10(3): 210-5.
55. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453(7198): 1122-6.
56. Abais JM, Xia M, Li G, Gehr TW, Boini KM, Li PL. Contribution of endogenously produced reactive oxygen species to the activation of podocyte NLRP3 inflammasomes in hyperhomocysteinemia. Free Radic Biol Med 2014; 67: 211-20.
57. Li PL. Cardiovascular pathobiology of inflammasomes: inflammatory machinery and beyond. Antioxid Redox Signal 2015;, 22(13): 1079-83.
58. Denes A, Lopez-Castejon G, Brough D. Caspase-1: is IL-1 just the tip of the ICEberg? Cell Death Dis 2012; 3: e338.
59. Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol 2011; 11(3): 213-20.
60. Lee MC, Miller EA, Goldberg J, Orci L, Schekman R. Bidirectional protein transport between the ER and Golgi. Annu Rev Cell Dev Biol 2004; 20: 87-123.
61. Trombetta ES, Parodi AJ. Quality control and protein folding in the secretory pathway. Annu Rev Cell Dev Biol 2003; 19: 649-76.
62. Nickel W, Rabouille C. Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol 2009; 10(2): 148-55.
63. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annual Rev Immunol 2009; 27: 519-50.
64. Gross O, Yazdi AS, Thomas CJ, et al. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36(3): 388-400.
65. Monack DM, Detweiler CS, Falkow S. Salmonella pathogenicity island 2-dependent macrophage death is mediated in part by the host cysteine protease caspase-1. Cell Microbiol 2001; 3(12): 825-37.
66. Artlett CM, Thacker JD. Molecular activation of the NLRP3 Inflammasome in fibrosis: common threads linking divergent fibrogenic diseases. Antioxid Redox Signal 2015; 22(13): 1162-75.
67. Creagh EM, O'Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006; 27(8): 352-7.
68. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140(6): 805-20.
69. Andersen K, Eltrich N, Lichtnekert J, Anders HJ, Vielhauer V. The NLRP3/ASC inflammasome promotes T-cell-dependent immune complex glomerulonephritis by canonical and noncanonical mechanisms. Kidney Int 2014; 86(5): 965-978.
70. Zhao J, Zhang H, Huang Y, et al. Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NFkappaB activation. Int Immunopharmacol 2013; 17(1): 116-22.
71. Lorenz G, Darisipudi MN, Anders HJ. Canonical and noncanonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant 2014; 29(1): 41-8.
72. Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in endstage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94(11): 2743-8.
73. Yi F, Zhang AY, Li N, et al. Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats. Kidney Int 2006; 70(1): 88-96.
74. Yi F, Xia M, Li N, Zhang C, Tang L, Li PL. Contribution of guanine nucleotide exchange factor Vav2 to hyperhomocysteinemic glomerulosclerosis in rats. Hypertension 2009; 53(1): 90-6.
75. Ingram AJ, Krepinsky JC, James L, et al. Activation of mesangial cell MAPK in response to homocysteine. Kidney Int 2004; 66(2): 733-45.
76. Woo CW, Siow YL, O K. Homocysteine induces monocyte chemoattractant protein-1 expression in hepatocytes mediated via activator protein-1 activation. J Biol Chem 2008; 283(3): 1282-92.
77. de la Sierra A, Larrousse M. Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens 2010; 24(6): 373-9.
78. Cheung GT, Siow YL, O K. Homocysteine stimulates monocyte chemoattractant protein-1 expression in mesangial cells via NFkappaB activation. Can J Physiol Pharmacol 2008; 86(3): 88-96.
79. Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest 2014; 124(6): 2333-40.
80. Awad AS, Kinsey GR, Khutsishvili K, Gao T, Bolton WK, Okusa MD. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am J Physiol Renal Physiol 2011; 301(6): F1358-66.
81. Shahzad K, Bock F, Dong W, et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int 2015; 87(1): 74-84.
82. Gao P, He FF, Tang H, et al. NADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia. J Diabetes Res 2015; 2015: 504761.
83. Hall JE, Henegar JR, Dwyer TM, et al. Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther 2004; 11(1): 41-54.
84. Boini KM, Zhang C, Xia M, et al. Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim Biophys Acta 2010; 1801(12): 1294-304.
85. Axelsson J, Heimburger O, Stenvinkel P. Adipose tissue and inflammation in chronic kidney disease. Contrib Nephrol 2006; 151: 165-74.
86. Hunley TE, Ma LJ, Kon V. Scope and mechanisms of obesityrelated renal disease. Curr Opin Nephrol Hypertens 2010; 19(3): 227-34.
87. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17(2): 179-88.
88. Boini KM, Xia M, Koka S, Gehr TW, Li PL. Instigation of NLRP3 inflammasome activation and glomerular injury in mice on the high fat diet: role of acid sphingomyelinase gene. Oncotarget 2016; 7(14): 19031-44.
89. Lambers Heerspink HJ, de Zeeuw D. Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 2013; 76(4): 536-50.
90. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Ann Rev Immunol 2009; 27: 621-68.
91. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008; 58(2): 631-3.
92. Terkeltaub R, Sundy JS, Schumacher HR, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 68(10): 1613-7.
93. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrinassociated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58(8): 2443-52.
94. Fleishmann RM. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents. Clin Exp Rheumatol 2002; 20(5 Suppl 27): S35-41.
95. Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 2010; 21(3): 157-63.
96. Hung AM, Ellis CD, Shintani A, et al. IL-1beta receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 2011; 22(3): 437-42.
97. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest 2005; 115(8): 2047-58.
98. Perregaux DG, McNiff P, Laliberte R, et al. Identification and characterization of a novel class of interleukin-1 posttranslational processing inhibitors. J Pharmacol Exp Ther 2001; 299(1): 187-97.
99. Kuipers MT, Aslami H, Janczy JR, et al. Ventilator-induced lung injury is mediated by the NLRP3 inflammasome. Anesthesiology 2012; 116(5): 1104-15.
100. Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009; 187(1): 61-70.
101. Lottaz D, Beleznay Z, Bickel M. Inhibition of ATP-binding cassette transporter downregulates interleukin-1beta-mediated autocrine activation of human dermal fibroblasts. J Invest Dermatol 2001; 117(4): 871-6.
102. Kerur N, Hirano Y, Tarallo V, et al. TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy. Invest Ophthalmol Vis Sci 2013; 54(12): 7395-401.